Rhythm Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
And thanks to everyone joining us here and on the phone as well as David Meeker, the CEO for Rhythm Pharmaceuticals. Thanks for joining us this morning. Perhaps we could get started just with a brief overview of the company, with a particular focus on what you see as key value drivers over the next, let's call it, 12 to 24 months.
Yes. Thank you, Corinne. Great to be here. So Rhythm Pharmaceuticals, we're working on a -- we have a precision therapy for a defect in the melanocortin-4 pathway, which is the pathway in our hypothalamus, which governs our food intake and our energy expenditure. So when we eat a meal, we got signaling from the gut to the brain that says you're full. It shouldn't be hungry anymore. You should stop eating and your energy expenditure should go up. Conversely, if you haven't eaten, that signaling occurs and it drives this feeling, a lack of [society] hunger and your energy expenditure has
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
